iBio could be a great long-term investment
iBio (IBIO) currently trades at $0.90 and has fallen by 3.47% today. IBIO went down $0.03 from the previous closing price of $0.93. The high forecast for iBio is $30.00 and the low is $3.00. The company’s market cap is $90.81 million with a 52 week high of $3.40 and a 52 week low of $0.05. IBIO has changed in price by 0.08 per share in the last 12 months. The company has recently joined the Alliance of Biosecurity and will be manufacturing vaccines in the future. They announced advancement on their COVID-19 vaccine program March 27. Ibio seems to be a safe investment moving forward.
iBio has a weak EPS of -1.58. This means the company lost $-1.58 per share after paying dividends, this can indicate that the stock is a risky investment. EPS is calculated as a company’s profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company’s profitability. It is common for a company to report EPS that is adjusted for extraordinary items and potential share dilution. Based on this information, investorsQ rates this stock 5 out of 10. We give it this rating based on current information written in this article.
iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health, including a virus-like particle (VLP) -based vaccine against SARS-CoV-2. iBio’s subsidiary, iBio CDMO is a global leader in plant-based manufacturing. It’s FastPharming™ and FastGlycaneering™ platforms provide contract development and manufacturing services via its 130,000 square foot facility in Bryan, Texas. The speed and scalability of FastPharming make it an ideal choice for other innovator companies who want to rapidly produce COVID-19 biologics.